AHA Scientific Sessions 2012: Aspirin Use & Recurrent VTE


The Particulars: Aspirin is commonly prescribed to patients with venous thromboembolism (VTE). The effects of aspirin on the risk of recurrent VTE have not been well established in clinical studies.

Data Breakdown: Researchers assessed the rate of recurrent VTE in 822 patients who were evenly randomized to placebo or aspirin. At an average of 37 months, 4.8% of patients in the aspirin group experience a recurrent VTE, compared with 6.5% in the placebo group. Although the difference was not significant, aspirin was shown to significantly reduce the risk of major vascular events—including a composite of VTE, myocardial infarction, stroke, or cardiovascular death—when compared with placebo (5.2% vs 8.0%),.

Take Home Pearl: Although aspirin does not appear to significantly reduce the rate of recurrent VTE when compared with placebo, it does appear to decrease the rate of major vascular events.


  1. AHA Scientific Sessions 2012 | Physician's Weekly - [...] Aspirin Use & Recurrent VTE [...]

Submit a Comment

Your email address will not be published. Required fields are marked *

two × 1 =